Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oncorus Inc (NQ: ONCR ) N/A UNCHANGED Last Price Updated: 11:52 AM EDT, Jun 20, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Oncorus Inc Oncorus Announces Workforce Reduction Plan June 01, 2023 From Oncorus, Inc. Via GlobeNewswire Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates May 22, 2023 From Oncorus, Inc. Via GlobeNewswire Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates March 24, 2023 From Oncorus, Inc. Via GlobeNewswire 4 Stocks With Huge Cash Holdings at Silicon Valley Bank March 13, 2023 How the recent failure of Silicon Valley Bank leaves several companies with significant deposits stuck in the bank. Will regulators step in and save the day? Via MarketBeat Topics ETFs Economy Exposures Interest Rates Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates January 04, 2023 From Oncorus, Inc. Via GlobeNewswire Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer November 30, 2022 From Oncorus, Inc. Via GlobeNewswire Oncorus to Participate in Upcoming Investor Conferences November 23, 2022 From Oncorus, Inc. Via GlobeNewswire Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting November 18, 2022 From Oncorus, Inc. Via GlobeNewswire Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates November 02, 2022 From Oncorus, Inc. Via GlobeNewswire Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer October 07, 2022 New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021 From Oncorus, Inc. Via GlobeNewswire DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility September 22, 2021 Clinical stage biopharmaceutical company focused on viral immunotherapies building out state-of-the-art, 88,000 square foot facility in Massachusetts BOSTON, MA / ACCESSWIRE / September 22, 2021 / DPS... From DPS Group - Boston Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
